The vaccine that the Military Sciences Academy from China has developed against the ebola disease has already been authorized to start the clinical testing phase in human beings.
The department of General Logistics from the Popular liberation Army, which was quoted by the official Xinhua news agency, has been authorized to carry out its tests and it is based on the stump with the genetic mutation from 2014 that has caused the current ebola epidemic to the west of Africa.
The substance is shaped as a freeze-dried dust which keeps it stable in temperatures of up to 37 degrees Centigrade and two weeks as a maximum time which enables its transportation through the West Africa and makes possible its production on a large scale.
According to the last numbers from the World Health Organization which were announced at the beginning of this month, that epidemic has caused more than 6.000 deaths thus far and the immense majority of them has been in the African west.
The ChAd4 Vaccine to be proven in Africa
That experimental vaccine against the ebola disease will not be proven in Africa until February.
After a meeting that was held between representatives from that laboratory, the neighbors and the World Health Organization, it has been decided the estimated date for the II phase of tests.
The information, which was requested from the GlaxoSmithKline about the ChAd3 prototype, should be analyzed by the end of January.
The nations, where that vaccine will be tested and have already prepared their own ethical and safe procedures, are Cameron, Ghana, Mali, Nigeria and Senegal, respectively.
The ChAd3 contains two genes of the Zaire type ebola virus. Moreover, the tests with animals were really promising ones.
As for the WHO the ChAd3 vaccine is one of the most promising vaccines that are announced on its web. The other one is the rVSV one and in spite of the vector used is different, it is a virus from the vesicular stomatitis; therefore, its way of acting is similar.
Another of the experimental vaccines is suspended
The EFE agency announced that the clinical test of one of the experimental vaccines against the ebola disease has been suspended given the fact that there have been some people inoculated who have experienced intense muscular pains, according to Mary-Paule Kienu, who is the general director of the World Health Organization.
It is about the VSV-ZEBOV vaccine which was developed by the Public Health Agency from Canada and its royalties currently belong to the Merck pharmaceutical company.
"There are some vaccine people who have experienced muscular pains which is something normal when there is a viral infection, but as a precaution, the researchers have decided to cancelled the related test for some weeks to get to know much more about the muscular pains." Kieny explained.
The aforementioned expert stated that there was no need to be worried about it given the fact that the related test was going to be suspended in the Christmas period, and it would be restarted in January, and that was something that had not been modified.
The study began on November 10th and on December 2nd the responsible people from the Cantonal de Ginebra Hospital, who are carrying out the study, announced some really positive results.
The muscular pains in hands and feet appeared between 10 and 15 days after having been vaccinated. Their symptoms lasted some days and disappeared later. The patients did not experience any other ailment.
Even though the pains are relatively normal after an immunization, they happens often that after the inoculation of the vaccine against the rubella, for instance, however, they had not been programmed; therefore, that reaction had not been informed to the voluntaries.
That is why that it is required to get to know their intensity and regularity and/or any other important detail to inform to future voluntary candidates so that they could get to know those very likely side effects in advance.
"The aforementioned cancellation is a standard procedure in any clinical test with human beings and that is why it is named as a test which is conceived to verify all and each of the side effects." Margaret Harris from the communication system of the WHO, explained.
At the beginning, there were 115 voluntaries that were going to participate in the test and about 50 voluntary ones have been vaccine to date given the hospital had only the capacity to receive 15 ones, weekly.
The requirements to be a voluntary are being adults aged between 18 and 65 years who should give their written consent and are healthy, as well as not being pregnant or breastfeeding if they were women.
"The test was organized into two groups and there was certain number of participants who received a placebo to rule out the false side effects, like it could be headache." The scientific explained.
Each voluntary received a unique dosage in their arm and the objective is to determine is their body create antibodies.
Translated by: JC Caballero / taken from radiorebelde.cu